A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment
National Cancer Institute (NCI)
Summary
Background: \- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers. The investigators are particularly interested in samples from individuals who have diseases that can be treated with a new type of drug called immunotoxin, in which an antibody carrying a toxin binds to a cancer cell and allows the toxin to kill the cell. Objectives: \- To collect a variety of clinical samples, including blood, urine, lymph samples, and other tissues, in order to study the samples and develop new treatments for leukemia. Eligibility: \- Individuals 18 years of age and older who have been diagnosed with leukemia or other kinds of blood and lymphatic system cancers, or who are healthy volunteers. Design: * Individuals who have leukemia will be asked to provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide only blood and urine samples. * No treatment will be given as part of this protocol.
Description
Background * Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biology (LMB). * HCL variants often resemble classic HCL but are more aggressive and less responsive to treatments, such as HCLv and IGHV4-34+ HCL that are immunophenotypically indistinguishable from classic HCL and highly aggressive and resistant like HCLv. * The investigators on this protocol are studying molecular and clinical aspects of HCL, and how…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Yes
* INCLUSION CRITERIA: All participants * 18 years of age and older * Desire of the individual to submit data and samples for research * Ability to understand and the willingness to sign a written informed consent document. Individuals with cancer -Participants may have a diagnosis of hematologic malignancy or solid tumor. These participants would not be excluded if they were in long-term complete remission. Normal donors (Individuals without cancer) -Individuals must not have a current or prior diagnosis of a hematologic malignancy or solid tumor. EXCLUSION CRITERIA: All participants…
Location
- National Institutes of Health Clinical CenterBethesda, Maryland